Priti Patel - 01 Feb 2023 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Signature
/s/ Sean Smith, Attorney-in-Fact for Priti Patel
Issuer symbol
NGNE
Transactions as of
01 Feb 2023
Net transactions value
-$8,588
Form type
4
Filing time
03 Feb 2023, 15:32:55 UTC
Previous filing
04 Aug 2022
Next filing
04 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NLTX Common Stock Options Exercise $0 +35,000 +335% $0.000000 45,462 01 Feb 2023 Direct F1
transaction NLTX Common Stock Sale $8,588 -14,380 -32% $0.5972 31,082 02 Feb 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Restricted Stock Units Options Exercise $0 -35,000 -50% $0.000000 35,000 01 Feb 2023 Common Stock 35,000 $0.000000 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,000 shares of Common Stock acquired by the Reporting Person on May 13, 2022 and 2,000 shares of Common Stock acquired by the Reporting Person on November 15, 2022 pursuant to the Issuer's employee stock purchase plan.
F2 The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3 Represents the weighted average sale price. The lowest price at which shares were sold was $0.576 and the highest price at which shares were sold was $0.635. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein.
F4 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F5 The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6 The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.